Skip to content
Review

Remimazolam Versus Propofol for Anesthesia Induction and Maintenance in Adult Cardiac Surgical Patients: A PRISMA-Compliant Systematic Review and Meta-analysis.

Oct 2026 · Journal of Cardiothoracic and Vascular Anesthesia · 0 citations · 21 references
Medicine

Abstract

Objectives

To compare remimazolam-based with propofol-based anesthesia for induction and maintenance in adult cardiac surgery.

Design

Systematic review and meta-analysis of randomized controlled trials.

Setting

Cardiovascular centers.

Participants

Adults undergoing cardiac surgery.

Interventions

Remimazolam-based versus propofol-based general anesthesia for induction and maintenance.

Measurements

AND MAIN

Results

Fourteen reports describing randomized trials, including three theses, contributed 1,773 reported participants to the primary synthesis. All were conducted in China, and no key pooled result was supported exclusively by results at low risk of bias. One terminated European registry-results trial (23 treated patients) was included as supplementary sensitivity evidence. Data on major postoperative morbidity and mortality were too sparse to pool. Remimazolam was associated with fewer trial-defined intraoperative hypotension events (odds ratio [OR], 0.31; 95% confidence interval [CI], 0.20-0.47; p < 0.001; I² = 0%) and fewer bradycardia events (OR, 0.20; 95% CI, 0.12-0.34; p < 0.001; I² = 0%). It was also associated with shorter mechanical ventilation duration (mean difference [MD], -1.84 hours; 95% CI, -2.34 to -1.35 hours; p < 0.001; I² = 71%). Hospital length of stay crossed the line of no effect (MD, -0.48 days; 95% CI, -0.99 to 0.02 days; p = 0.06; I² = 37%). Certainty of evidence was very low for the hemodynamic and mechanical ventilation findings.

Conclusions

Across the cardiac surgical populations represented in the included trials, remimazolam was associated with fewer trial-defined intraoperative hypotension and bradycardia events and shorter mechanical ventilation duration. The certainty of evidence for these associations was very low. The evidence does not establish improved major morbidity or mortality. Future multicenter confirmation is required.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.